A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced NSCLC Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Pembrolizumab (Primary) ; Docetaxel; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jun 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 05 Jun 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 22 Mar 2017 New trial record